- Home
- SLNH vs SNY Comparison
SLNH vs SNY Comparison
Compare SLNH & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLNH | SNY |
|---|---|---|
| Founded | 1961 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.5M | 104.5B |
| IPO Year | 2005 | 2001 |
Fundamental Metrics
Financial Performance| Metric | SLNH | SNY |
|---|---|---|
| Price | $1.17 | $42.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $5.00 | ★ $58.00 |
| AVG Volume (30 Days) | ★ 9.0M | 2.1M |
| Earning Date | 05-15-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.47% |
| EPS Growth | ★ 80.41 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $38,021,000.00 | N/A |
| Revenue This Year | $55.83 | $3.49 |
| Revenue Next Year | N/A | $6.10 |
| P/E Ratio | ★ N/A | $6.14 |
| Revenue Growth | ★ 80.49 | N/A |
| 52 Week Low | $0.59 | $40.89 |
| 52 Week High | $5.14 | $52.68 |
Technical Indicators
Market Signals| Indicator | SLNH | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 47.69 | 35.98 |
| Support Level | $1.08 | $42.30 |
| Resistance Level | $1.41 | $45.22 |
| Average True Range (ATR) | 0.09 | 0.59 |
| MACD | 0.01 | -0.30 |
| Stochastic Oscillator | 44.83 | 2.33 |
Price Performance
Historical ComparisonAbout SLNH Soluna Holdings Inc.
Soluna Holdings Inc is a U.S.-based company engaged in the development and operation of data centers powered by renewable energy. The company utilizes excess or curtailed energy from renewable sources to support high-performance computing applications, including cryptocurrency mining, artificial intelligence, and machine learning. Its business model focuses on converting underutilized renewable energy into computing resources through co-located data center infrastructure.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.